Methods, processes and systems for procuring, isolating and cryopreserving at least one viable, multipotent maternal placental stem cell is provided. Viable maternal placental stem cells are also provided. The maternal placental stem cell of the invention expresses the cell surface marker CD117 and at least one of the cell surface markers selected from the group consisting of CD29, CD44, CD73, CD90, CD105, CD166, SSEA-3 and SSEA-4 and has low or no expression of at least one of the cell surface markers selected from the group consisting of CD34, CD45, CD133, TRA-1-60 and TRA-1-81. The methods and process comprise generally obtaining a piece of placental tissue from a whole placenta, disaggregating the placental tissue with mechanical separation or enzymatic digestion, collecting and concentrating placental cells comprising maternal placental cells with centrifugation and optionally cryopreserving the placental cells. Additional steps for selecting and culturing the maternal placental stem cells is provided.
Procurement, Isolation And Cryopreservation Of Endometrial/Menstrual Cells
Mercedes A. Walton - Mendham NJ, US Julie G. Allickson - Odessa FL, US
Assignee:
Cryo-Cell International, Inc. - Oldsmar FL
International Classification:
A61K 35/12 C12N 5/06 C12Q 1/02 C12M 1/00
US Classification:
424 937, 435325, 4353081, 435374, 435 29
Abstract:
Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefor are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II.
Infectious Diseases Testing Of Menstrual Fluid, Endometrial/Menstrual Cells, Amniotic Fluid, Umbilical Cord Blood Or Other Samples
Mercedes A. Walton - Mendham NJ, US Julie G. Allickson - Odessa FL, US
Assignee:
Cryo-Cell International, Inc. - Oldsmar FL
International Classification:
C12Q 1/02 G01N 33/68
US Classification:
435 29, 436 86
Abstract:
Methods are provided for obtaining and testing or analyzing a non-venous and non-arterial puncture human fluid or cell sample or human body fluid or cell sample to detect the presence of at least one infectious disease. The sample may be menstrual fluid, endometrial menstrual cells, umbilical cord blood, or amniotic fluid. Confirmatory testing of a corresponding arterial or venous blood sample for comparison to the test results for the non-venous and non-arterial human fluid or cell sample may be performed. The testing may comprise a screening test or a confirmatory test.
Methods For Co-Culturing Cord Blood Derived Cells With Menstrual Stem Cells
Mercedes A. Walton - Mendham NJ, US Julie G. Allickson - Odessa FL, US
Assignee:
Cryo-Cell International, Inc. - Oldsmar FL
International Classification:
C12N 5/08
US Classification:
435372
Abstract:
Methods are provided for obtaining expanded human cord blood cells expressing CD34. The methods involve seeding a sufficient amount of cord blood cells with a sufficient amount of menstrual cells under co-culture conditions suitable to promote expansion of the cord blood cells, and co-culturing the cord blood cells with the menstrual cells under culture conditions that support at least two or more population doublings of the cord blood cells. Methods are also provided for growing expanded human cord blood cells to give rise to any one of colony forming units, colony forming unit granulocyte macrophages (CFU-GM), burst forming unit erythroids (BFU-E), and colony forming unit granulocyte erythrocyte macrophage megakaryocyte (CFU-GEMM) blood lineage precursor cells. The expanded cells may express CD34, SSEA-4, and HLA-II. Compositions of the expanded cells are also provided.
Procurement, Isolation, And Cryopreservation Of Endometrial/Menstrual Cells
Mercedes A. Walton - Oldsmar FL, US Julie G. Allickson - Oldsmar FL, US
Assignee:
Cryo-Cell International, Inc. - Oldsmar FL
International Classification:
A61K 35/12 C12N 5/00 C12N 5/02
US Classification:
424 937, 435325, 435374
Abstract:
Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefor are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II.
Methods Of Treating Stroke Using Stem Cell-Like Menstrual Blood Cells
Paul R. Sanberg - Spring Hill FL, US Cesario V. Borlongan - Odessa FL, US Julie Allickson - Odessa FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL SANERON CCEL THERAPEUTICS, INC. - Tampa FL MEDICAL COLLEGE OF GEORGIA - Augusta GA
International Classification:
A61K 35/14 A61P 9/10 A61K 38/18
US Classification:
424 937, 514 81, 514 84
Abstract:
A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats.
Procurement, Isolation And Cryopreservation Of Fetal Placental Cells
Methods, processes and systems for procuring, isolating and cryopreserving fetal placental cells are provided. A population of fetal placental cells is also provided.
Youtube
Advanced Therapies and the FDAs RMAT Designat...
An introduction to the FDA's RMAT designation with Dr Julie Allickson,...
Duration:
2m
Mayo Clinic Q&A podcast: Manufacturing new tr...
... Julie Allickson, the Michael S. and Mary Sue Shannon Family Direct...
Duration:
19m 8s
Panel 2 - Overview of the Landscape Regener...
... Regenerative Medicine and Cell Therapies Event Date: September 16,...